AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses
ABBVie will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology Annual Meeting and the virtual European Hematology Association congress . “We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment,” said Mohamed Zaki M.D., Ph.D., vice president and global head of oncology development, AbbVie. “We …
– ABBVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting ( June 4-8 ) and the virtual European Hematology Association (EHA) congress ( June 9-17 ).
DGAP-News: MorphoSys AG: MorphoSys präsentiert Daten zu Tafasitamab (Monjuvi(R)) auf der ASCO-Jahrestagung 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NOXXON Pharma N V : NOXXON KÜNDIGT SEINE TEILNAHME AM 7 JÄHRLICHEN IMMUNONKOLOGISCHEN INNOVATIONSFORUM VOM 18 BIS 20 MAI 2021 AN
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(1)
Ultimovacs ASA ( Ultimovacs ) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in
Frontiers in Immunology of its positive long-term Overall Survival (OS) data from the Phase I trial evaluating the Company s universal cancer vaccine, UV1, in combination with checkpoint inhibitor ipilimumab in patients with metastatic malignant melanoma. As published in the journal, in addition to the achievement of the primary endpoints of safety and tolerability, 50% of the patients were still alive at the data cut-off, supporting the combination of the Company s proprietary UV1 vaccine with ipilimumab, a CTLA-4 checkpoint inhibitor and standard-of-care treatment, in this late-stage patient population.